CDMO
Scope
Date
~
-
Bio & Pharma
S.Korea’s GC Cell targets global cell therapy CDMO business
GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Pharmteco launches new viral vector platforms, key for CGT
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two...
Nov 22, 2023 (Gmt+09:00)
-
Bio & Pharma
South Korean bio, pharma industry set to take leap
South Korea’s chemical maker LG Chem Ltd. is expected to reap more than 1 trillion won ($768.5 million) in sales this year from its new growth...
Nov 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Lotte Biologics to break ground on 1st local CDMO plant in 2024
South Korea’s Lotte Biologics Co. is set to start building its first local facility for drug manufacturing next year, aiming for 400,000 liter...
Oct 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biologics partners with Indian company for CDMO
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...
Sep 22, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
IMM PE invites potential buyers for Genuone worth $752 mn
South Korea’s top-tier contract drugmaker Genuone Sciences Inc. with an estimated value of up to 1 trillion won ($752 million) is smooth saili...
Sep 13, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Pharmteco gears up for big leap in advanced biotherapies
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is upping the ante in its b...
Aug 17, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience buys 6.5 million Novavax shares for $83.4 million
SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...
Aug 09, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Pharmteco secures 12 global pharma clients, sets up US R&D center
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...
Aug 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics, Pfizer sign $411.3 mn agreement for long-term CDMO
Samsung Biologics Co., the world’s No. 1 contract drugmaker, announced a groundbreaking strategic partnership with Pfizer on Thursday, marking...
Jun 08, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics to double production by 2032; eyes ADCs, M&As
BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...
Jun 07, 2023 (Gmt+09:00)
-
Bio & Pharma
BIO USA 2023 to draw S.Korean biotech leaders, startups
More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...
May 30, 2023 (Gmt+09:00)
-
Pre-IPOs
SK Pharmteco again seeks $382 mn in pre-IPO funding
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), is eyeing pre-initial public offering funding again after it dropped...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics to invest $1.5 bn for 5th CDMO factory
Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investm...
Mar 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Prestige Biologics attracts $59 mn overseas investment
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...
Mar 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Medipost, OmniaBio to enhance cooperation for CDMO business
South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...
Dec 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics in CDO deal talks with global pharma firm
FRANKFURT – Samsung Biologics Co., the world’s largest contract drugmaker, is in talks to develop medicines for a global pharmaceutical ...
Nov 07, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost to expand CDMO business with 10 new clean rooms in Korea
Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO)...
Oct 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics opens the world's largest CDMO factory
South Korea’s Samsung Biologics Co.’s new biopharmaceuticals plant launched operations on Tuesday, a move expected to widen the gap betw...
Oct 11, 2022 (Gmt+09:00)
-
Bio & Pharma
K-bio firms embrace gene therapy CDMO as Samsung looks the other way
South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanis...
Aug 05, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics to double CDMO capacity with new plants worth $5.3 bn
Samsung Biologics Co., the world’s largest contract drugmaker, plans to double its manufacturing capacity by building four additional plants w...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Samsung Biologics eye record-high annual sales
South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...
Jul 08, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost acquires Canada’s OmniaBio for CDMO business
Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...
May 31, 2022 (Gmt+09:00)
-
Biotech
SK invests $350 mn in US CDMO firm
SK Inc., the holding company of SK Group, announced Sunday that it invested $350 million into Pennsylvania-based Center for Breakthrough Medicines (...
Jan 10, 2022 (Gmt+09:00)
-
Pre-IPOs
SK Pharmteco to raise up to $498 mn on $5 bn valuation
SK Pharmteco, a contract development and manufacturing organization (CDMO) for pharmaceuticals, is slated to raise 400 billion ($332.2 million) to 6...
Jan 10, 2022 (Gmt+09:00)
-
Pharamaceuticals
Korea’s CHA Biotech to triple US CDMO capacity
CHA Biotech, South Korea’s stem cell therapeutics developer, is set to expand its biomaterials contract development and manufacturing organiza...
Jan 05, 2022 (Gmt+09:00)